The ideal goal of hepatitis B treatment is to achieve a functional cure,and the persistent cccDNA in the liver is a barrier to functional cure.Currently,antiviral drugs represented by pegylated interferon-α and nucleos(t)ide analogues cannot eliminate cccDNA,which is difficult to achieve functional cure.With the deepening of the exploration of various mechanisms and drug targets,significant progress has been made in the research and development of several novel drugs targeting the hepatitis B virus's life cycle and immune system,offering hope for a functional cure.This article presents an overview of the new progress in clinical research on antiviral therapy for chronic hepatitis B based on the literature published in recent years and international conference materials.
维普
万方数据